MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci183656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Yu-Wen Cai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fudan University Shanghai Cancer Center and Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan U…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Mutation, MAP Kinase Kinase Kinase 1. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR + /HER2 − ) breast cancer, the most common type of breast cancer, has faced challenges such as endocrine therapy resistance and distant relapse. Immunotherapy has shown progress in treating triple-negative breast cancer, but immunological research on HR + /HER2 – breast cancer is still in its early stages. Here, we performed a multi-omics analysis of a large cohort of patients with HR + /HER2 – breast cancer ( n = 351) and revealed that HR + /HER2 – breast cancer possessed a highly heterogeneous tumor immune microenvironment. Notably, the immunological heterogeneity of HR + /HER2 – breast cancer was related to mitogen-activated protein kinase kinase kinase 1 ( MAP3K1 ) mutation and we validated experimentally that a MAP3K1 mutation could attenuate CD8 + T cell–mediated antitumor immunity. Mechanistically, MAP3K1 mutation suppressed MHC-I–mediated tumor antigen presentation through promoting the degradation of antigen peptide transporter 1/2 ( TAP1 / 2 ) mRNA, thereby driving tumor immune escape. In preclinical models, the postbiotic tyramine could reverse the MAP3K1 mutation–induced MHC-I reduction, thereby augmenting the efficacy of immunotherapy. Collectively, our study identified the vital biomarker driving the immunological heterogeneity of HR + /HER2 – breast cancer and elucidated the underlying molecular mechanisms, which provided the promise of tyramine as what we believe to be a novel therapeutic strategy to enhance the efficacy of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Fudan University Shanghai Cancer Center and Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Key Laboratory of Breast Cancer in Shanghai, Shanghai, China.
- Department of Breast Surgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cai, Y. W., Liu, C. C., Zhang, Y. W., Liu, Y. M., Chen, L., Xiong, X., Shao, Z. M., & Yu, K. D. (2025). MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci183656
Vancouver
Cai YW, Liu CC, Zhang YW, Liu YM, Chen L, Xiong X, et al. MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci183656
BibTeX
@article{Cai2025,
author = {Cai, Yu-Wen and Liu, Cui-Cui and Zhang, Yan-Wu and Liu, Yi-Ming and Chen, Lie and Xiong, Xin and Shao, Zhi-Ming and Yu, Ke-Da},
title = {MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci183656}
}
EUVIMED